591 related articles for article (PubMed ID: 26078391)
41. Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.
Probst BL; McCauley L; Trevino I; Wigley WC; Ferguson DA
PLoS One; 2015; 10(8):e0135257. PubMed ID: 26301506
[TBL] [Abstract][Full Text] [Related]
42. Molecular effects of cancer-associated somatic mutations on the structural and target recognition properties of Keap1.
Khan H; Killoran RC; Brickenden A; Fan J; Yang D; Choy WY
Biochem J; 2015 Apr; 467(1):141-51. PubMed ID: 25582950
[TBL] [Abstract][Full Text] [Related]
43. Nrf2-Keap1 antioxidant defense and cell survival signaling are upregulated by 17β-estradiol in homocysteine-treated dopaminergic SH-SY5Y cells.
Chen CS; Tseng YT; Hsu YY; Lo YC
Neuroendocrinology; 2013; 97(3):232-41. PubMed ID: 22948038
[TBL] [Abstract][Full Text] [Related]
44. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer.
Delgobo M; Gonçalves RM; Delazeri MA; Falchetti M; Zandoná A; Nascimento das Neves R; Almeida K; Fagundes AC; Gelain DP; Fracasso JI; Macêdo GB; Priori L; Bassani N; Bishop AJR; Forcelini CM; Moreira JCF; Zanotto-Filho A
Free Radic Biol Med; 2021 Dec; 177():58-71. PubMed ID: 34673143
[TBL] [Abstract][Full Text] [Related]
45. Nrf2: friend and foe in preventing cigarette smoking-dependent lung disease.
Müller T; Hengstermann A
Chem Res Toxicol; 2012 Sep; 25(9):1805-24. PubMed ID: 22686525
[TBL] [Abstract][Full Text] [Related]
46. Role of NRF2 in Lung Cancer.
Sánchez-Ortega M; Carrera AC; Garrido A
Cells; 2021 Jul; 10(8):. PubMed ID: 34440648
[TBL] [Abstract][Full Text] [Related]
47.
Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
[TBL] [Abstract][Full Text] [Related]
48. TRIM13 inhibits cell proliferation and induces autophagy in lung adenocarcinoma by regulating KEAP1/NRF2 pathway.
Yu B; Zhou Y; He J
Cell Cycle; 2023 Jun; 22(12):1496-1513. PubMed ID: 37245083
[TBL] [Abstract][Full Text] [Related]
49. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.
Konstantinopoulos PA; Spentzos D; Fountzilas E; Francoeur N; Sanisetty S; Grammatikos AP; Hecht JL; Cannistra SA
Cancer Res; 2011 Aug; 71(15):5081-9. PubMed ID: 21676886
[TBL] [Abstract][Full Text] [Related]
50. Suppression of radiation-induced migration of non-small cell lung cancer through inhibition of Nrf2-Notch Axis.
Zhao Q; Mao A; Guo R; Zhang L; Yan J; Sun C; Tang J; Ye Y; Zhang Y; Zhang H
Oncotarget; 2017 May; 8(22):36603-36613. PubMed ID: 28402268
[TBL] [Abstract][Full Text] [Related]
51. Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment.
Best SA; De Souza DP; Kersbergen A; Policheni AN; Dayalan S; Tull D; Rathi V; Gray DH; Ritchie ME; McConville MJ; Sutherland KD
Cell Metab; 2018 Apr; 27(4):935-943.e4. PubMed ID: 29526543
[TBL] [Abstract][Full Text] [Related]
52. A novel shogaol analog suppresses cancer cell invasion and inflammation, and displays cytoprotective effects through modulation of NF-κB and Nrf2-Keap1 signaling pathways.
Gan FF; Ling H; Ang X; Reddy SA; Lee SS; Yang H; Tan SH; Hayes JD; Chui WK; Chew EH
Toxicol Appl Pharmacol; 2013 Nov; 272(3):852-62. PubMed ID: 23899529
[TBL] [Abstract][Full Text] [Related]
53. Microenvironmental Activation of Nrf2 Restricts the Progression of Nrf2-Activated Malignant Tumors.
Hayashi M; Kuga A; Suzuki M; Panda H; Kitamura H; Motohashi H; Yamamoto M
Cancer Res; 2020 Aug; 80(16):3331-3344. PubMed ID: 32636316
[TBL] [Abstract][Full Text] [Related]
54. A Naturally-Occurring Dominant-Negative Inhibitor of Keap1 Competitively against Its Negative Regulation of Nrf2.
Qiu L; Wang M; Zhu Y; Xiang Y; Zhang Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30042301
[TBL] [Abstract][Full Text] [Related]
55. [The UGT1A, Nrf2 and Keap1 protein expression and significance in colon tumor].
Wang M; Qi YY; Chen S; Liu L; Chen J; Li YQ
Zhonghua Nei Ke Za Zhi; 2012 Jul; 51(7):531-5. PubMed ID: 22943825
[TBL] [Abstract][Full Text] [Related]
56. Oxidative stress-regulated lentiviral TK/GCV gene therapy for lung cancer treatment.
Leinonen HM; Ruotsalainen AK; Määttä AM; Laitinen HM; Kuosmanen SM; Kansanen E; Pikkarainen JT; Lappalainen JP; Samaranayake H; Lesch HP; Kaikkonen MU; Ylä-Herttuala S; Levonen AL
Cancer Res; 2012 Dec; 72(23):6227-35. PubMed ID: 23041549
[TBL] [Abstract][Full Text] [Related]
57. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M
Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899
[TBL] [Abstract][Full Text] [Related]
58. CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells.
Wang Q; Ma J; Lu Y; Zhang S; Huang J; Chen J; Bei JX; Yang K; Wu G; Huang K; Chen J; Xu S
Oncogene; 2017 Sep; 36(37):5321-5330. PubMed ID: 28534518
[TBL] [Abstract][Full Text] [Related]
59. Continuous activation of Nrf2 and its target antioxidant enzymes leads to arsenite-induced malignant transformation of human bronchial epithelial cells.
Yang X; Wang D; Ma Y; Xu X; Zhu Z; Wang X; Deng H; Li C; Chen M; Tong J; Yamanaka K; An Y
Toxicol Appl Pharmacol; 2015 Dec; 289(2):231-9. PubMed ID: 26420645
[TBL] [Abstract][Full Text] [Related]
60. Time course of Keap1-Nrf2 pathway expression after experimental intracerebral haemorrhage: correlation with brain oedema and neurological deficit.
Shang H; Yang D; Zhang W; Li T; Ren X; Wang X; Zhao W
Free Radic Res; 2013 May; 47(5):368-75. PubMed ID: 23438812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
